p-SCN-Bn-HEHA for Actinium
p-SCN-Bn-HEHA is a high-purity chelator for Actinium-225 and other radiometals, featuring a HEHA core specifically for strong multidentate binding and a p-SCN-Bn group for site-specific amine conjugation. It specifically provides robust in vivo stability, efficient radiolabeling, and reliable targeting for radioimmunotherapy and nuclear medicine.
Key Features and Benefits
-
HEHA Chelator: Strong, multidentate coordination for Actinium-225 and other large radiometals.
-
p-SCN-Bn Group: Enables site-specific conjugation to amine-containing biomolecules.
-
High Radiochemical Stability: Minimizes release of Actinium in biological systems.
-
Optimized for α-therapy: Suitable for targeted alpha-particle radiotherapy.
-
High Purity: Supplied at >95% purity for reproducibility and GMP-compliant workflows.
Applications
-
Targeted alpha therapy (TAT) with Actinium-225.
-
Development of radiolabeled antibodies, peptides, and ligands.
-
Radiotracer synthesis for nuclear medicine imaging and therapy.
-
Research in chelator optimization for heavy radiometals.
Storage and Handling
-
Storage: Store at –20 °C, dry, and protected from light.
-
Handling: Use anhydrous buffers for conjugation; avoid strong oxidizing or reducing agents.
This product combines a high-affinity HEHA chelator with a reactive p-SCN-Bn group for stable radiometal binding and site-specific bioconjugation, specifically enabling reliable preparation of targeted alpha-therapy agents.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
